Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics (HOWL) director Luke Evnin reported open‑market sales of common stock made under a Rule 10b5‑1 plan dated September 24, 2025. The sales occurred on 10/30/2025, 10/31/2025, and 11/03/2025.
He sold 55,795 shares at a weighted average price of $1.43 (range $1.365–$1.55), 73,192 shares at $1.28 (range $1.205–$1.415), and 60,369 shares at $1.29 (range $1.245–$1.33). Following these transactions, 3,943,359 shares were reported as beneficially owned indirectly through affiliated entities.
Werewolf Therapeutics (HOWL): A reporting group affiliated with MPM BioImpact/MPM BioVentures, identified as a Director and 10% Owner, reported open‑market sales executed under a Rule 10b5‑1 plan dated September 24, 2025. The group sold 86,936 shares on 10/30/2025 at a weighted average price of $1.43, 114,044 shares on 10/31/2025 at $1.28, and 94,063 shares on 11/03/2025 at $1.29.
Following these transactions, the group reported indirect beneficial ownership of 6,355,717 shares, then 6,241,673 shares, and 6,147,610 shares, respectively. Footnotes state the sales were made across multiple affiliated entities, with price ranges of $1.365–$1.55 on 10/30, $1.205–$1.415 on 10/31, and $1.245–$1.33 on 11/03, and that each reporting person disclaims beneficial ownership beyond pecuniary interest.
Werewolf Therapeutics (HOWL): A director and 10% owner reported open‑market sales executed under a Rule 10b5‑1 plan dated September 24, 2025. The transactions were: 86,936 shares at a weighted average price of $1.43 on October 30, 2025; 114,044 shares at a weighted average price of $1.28 on October 31, 2025; and 94,063 shares at a weighted average price of $1.29 on November 3, 2025.
Following these sales, the filer reported 6,147,610 shares beneficially owned indirectly. The filing lists multiple affiliated entities as holders and confirms the plan‑based nature of the trades.
Werewolf Therapeutics (HOWL) director Luke Evnin reported open‑market sales of common stock executed under a Rule 10b5‑1 plan dated September 24, 2025.
He sold 46,664 shares on 10/27/2025 at a weighted average price of $1.72, 44,327 shares on 10/28/2025 at $1.64, and 86,154 shares on 10/29/2025 at $1.55. Following these transactions, he beneficially owned 4,132,715 shares indirectly.
Footnotes state the sales were made across affiliated entities and that prices reflect weighted averages with full trade‑level details available upon request.
Werewolf Therapeutics (HOWL): insider sales reported by MPM-affiliated holders. Reporting persons associated with MPM BioImpact/MPM BioVentures, identified as a Director and 10% Owner, disclosed open‑market sales executed pursuant to a Rule 10b5‑1 plan dated September 24, 2025.
Sales occurred on three dates: 72,709 shares on 10/27/2025 at a weighted average price of $1.72 (individual trades ranged $1.675–$1.82); 69,068 shares on 10/28/2025 at a weighted average price of $1.64 (range $1.605–$1.70); and 134,240 shares on 10/29/2025 at a weighted average price of $1.55 (range $1.51–$1.62).
Following these transactions, the reporting group’s beneficial ownership (indirect) was 6,645,961 shares after 10/27, 6,576,893 shares after 10/28, and 6,442,653 shares after 10/29, held across affiliated funds as detailed in the footnotes.
Werewolf Therapeutics (HOWL): Insider Form 4 filing reports sales by entities affiliated with MPM/UBS Oncology, identified as a director and 10% owner. The transactions were made pursuant to a Rule 10b5-1 plan dated September 24, 2025.
On October 27, 2025, 72,709 shares were sold at a weighted average price of $1.72 (range $1.675–$1.82), leaving 6,645,961 shares beneficially owned. On October 28, 2025, 69,068 shares were sold at a weighted average price of $1.64 (range $1.605–$1.70), leaving 6,576,893 shares beneficially owned. On October 29, 2025, 134,240 shares were sold at a weighted average price of $1.55 (range $1.51–$1.62), leaving 6,442,653 shares beneficially owned.
The filing attributes sales and post-transaction holdings across several affiliated funds and managers and notes that each reporting person disclaims beneficial ownership beyond their pecuniary interest.
Werewolf Therapeutics, Inc. reported a material event notifying that it is presently non-compliant with Nasdaq listing rule 5605(c)(2) because of the passing of director Dr. Lazarus. The company cites Nasdaq Listing Rule 5605(c)(4)(B), which provides a cure period to restore compliance. That cure period will end on the earlier of the company’s next annual meeting of stockholders or September 30, 2026. The filing is signed by Timothy W. Trost, Chief Financial Officer and Treasurer.
PFM Health Sciences and related entities report owning 401,110 shares (0.9%) of Werewolf Therapeutics, Inc. (HOWL). The filing states that PFM Health Sciences, LP, PFM Health Sciences GP, LLC, Partner Asset Management, LLC and Brian D. Grossman may each be deemed to beneficially own 401,110 shares, representing 0.9% of the 44,873,646 shares outstanding used for the calculation. All reporting persons indicate no sole voting or dispositive power and 401,110 shares of shared voting and dispositive power. The statement clarifies the relationships among the entities and includes a certification that the securities were not acquired to influence control.
Werewolf Therapeutics (HOWL) reported continued clinical progress while managing a substantial cash burn. The company held $77.6 million of cash and cash equivalents and
The company advanced its lead programs: WTX-124 has a selected recommended dose and active monotherapy and combination expansion arms with interim data planned for the second half of 2025, and WTX-330 completed Phase 1 and initiated a Phase 1b/2 trial, dosing its first patient. Operating expense reductions versus prior year reflect lower manufacturing and R&D spend for select programs, partially offset by continued clinical and development costs.
Balance sheet and financing items include a $30.0 million term loan carrying a high effective interest cost (reported effective rate ~19.24%) with embedded conversion features and a derivative liability. Management states additional funding will be necessary beyond the 12-month runway to continue development activities.
Werewolf Therapeutics announced that it furnished a press release reporting its financial results for the quarter ended June 30, 2025, and that the press release is provided as Exhibit 99.1. The company also made an updated corporate investor presentation publicly available and furnished it as Exhibit 99.2. The filing specifies that these items are being furnished rather than filed under the Exchange Act and includes a standard cautionary note describing forward-looking statements and associated development, regulatory, and financing risks.
The 8-K does not include the financial figures within its text but notifies investors where the results and presentation are available as exhibits for review.